1. Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation. Issue 3 (3rd May 2016) Authors: Cholon, Deborah M.; Esther, Charles R.; Gentzsch, Martina Journal: Expert review of precision medicine and drug development Issue: Volume 1:Issue 3(2016) Page Start: 235 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Established and novel human translational models to advance cystic fibrosis research, drug discovery, and optimize CFTR-targeting therapeutics. (June 2022) Authors: Cholon, Deborah M.; Gentzsch, Martina Journal: Current opinion in pharmacology Issue: Volume 64(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Personalised medicine for non-classic cystic fibrosis resulting from rare CFTR mutations. Issue 1 (30th July 2020) Authors: McCravy, Matthew S.; Quinney, Nancy L.; Cholon, Deborah M.; Boyles, Susan E.; Jensen, Timothy J.; Aleksandrov, Andrei A.; Donaldson, Scott H.; Noone, Peadar G.; Gentzsch, Martina Journal: European respiratory journal Issue: Volume 56:Issue 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. The cystic fibrosis airway milieu enhances rescue of F508del in a pre-clinical model. Issue 6 (20th December 2018) Authors: Gentzsch, Martina; Cholon, Deborah M.; Quinney, Nancy L.; Boyles, Susan E.; Martino, Mary E.B.; Ribeiro, Carla M.P. Journal: European respiratory journal Issue: Volume 52:Issue 6(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗